Alexandria Venture Investments
Strategic venture capital arm of Alexandria Real Estate Equities (NYSE - ARE), the leading life science real estate company. Invests in life science companies, often current or prospective tenants of Alexandria's innovation campuses.
Location
Pasadena, USA
Founded
2006
AUM
$1.8B+
Investment Range
$5M - $50M
Portfolio Companies
6
Focus
cvc
Fund Stages
seed, series-a, series-b, series-c, growth
Investment Thesis
Alexandria Venture Investments provides strategic capital to life science companies across all stages, with a focus on companies that align with Alexandria's real estate ecosystem. They leverage their unique position as both landlord and investor to provide companies with capital, lab space, and access to their extensive network of life science companies and talent.
Team
Partners / Managing Directors (Health & Bio Focus)
- Joel S. Marcus - Executive Chairman & Founder
- Peter Moglia - Co-CEO & CIO
- Aaron Jacobson - Managing Director, Venture Investments
Other Key Team Members
- Dean Shigenaga - President
Focus Areas
- Therapeutics
- Life Science Tools
- Diagnostics
- Digital Health
- Medical Devices
- Synthetic Biology
- Cell & Gene Therapy
Notable Exits
- Adaptive Biotechnologies - IPO (2019, NASDAQ: ADPT)
- Grail - Acquired (2021, by Illumina)
- Denali Therapeutics - IPO (2017, NASDAQ: DNLI)
- Agios Pharmaceuticals - IPO (2013, NASDAQ: AGIO)
Sources
- https://www.are.com/venture-investments.html
- https://www.are.com/people.html
- https://www.crunchbase.com/organization/alexandria-venture-investments
- Alexandria Real Estate Equities SEC Filings
Portfolio Companies
| Name | Location | Founded | Categories |
|---|---|---|---|
| Affinia Therapeutics | - | - | gene-therapybiotech+1 |
| MOMA Therapeutics | Cambridge, Massachusetts, USA | 2019 | therapeuticsbiotech+3 |
| Ventus Therapeutics | Waltham, Massachusetts, USA | 2018 | therapeuticsbiotech+3 |
| Capstan Therapeutics | San Diego, California, USA | 2019 | cell-therapygene-therapy+3 |
| Creyon Bio | San Diego, California, USA | 2020 | ai-mltherapeutics+4 |
| Remix Therapeutics | Cambridge, Massachusetts, USA | 2018 | rna-therapeuticsbiotech+3 |